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Introduction {#sec001}
============

Liver fibrosis is a major chronic liver disease that can progress to more severe liver cirrhosis and eventually cause hepatocellular carcinoma, accompanied by significant mortality \[[@pbio.3000563.ref001], [@pbio.3000563.ref002]\]. Sufficient evidence supports the hypothesis that liver fibrosis is the consequence of the wound-healing response, which maintains the original architecture to accommodate the compensatory proliferation of hepatocytes \[[@pbio.3000563.ref003]\]. It is worth noting that despite the annual increases in the prevalence and risk of liver fibrosis, especially in Asian countries, there is no proven effective treatment strategy to date \[[@pbio.3000563.ref004]\]. Thus, further understanding of the molecular pathophysiology of liver fibrosis and development of mechanism-based therapeutics are urgently needed.

Several studies to date have demonstrated that hepatic inflammation plays an important role in the underlying pathogenesis of liver fibrosis, which subsequently leads to the recruitment and activation of hepatic stellate cells (HSCs) as well as the excess production of extracellular matrix (ECM) proteins \[[@pbio.3000563.ref002], [@pbio.3000563.ref005], [@pbio.3000563.ref006]\]. In addition, inflammation acts as a fuel to accelerate liver cell proliferation and tissue regeneration. During fibrotic liver diseases, diverse hepatic immune cells, especially macrophages, are dynamically recruited to the injury site in a manner mainly determined by the cytokines and chemokines (C-C motif chemokine ligand 2 \[CCL2\], C-C motif chemokine ligand 5 \[CCL5\], C-X-C motif chemokine ligand 10 \[CXCL10\], etc.) secreted by hepatocytes, HSCs, and endothelial cells \[[@pbio.3000563.ref002]\]. These inflammatory factors control the migration and positioning of immune cells and HSCs, which express chemokine receptors, thus defining the magnitude of the inflammatory response during fibrosis progression. Among these chemokines, CCL2 is the most widely studied. The important role of the CCL2-C-C motif chemokine receptor 2 \[CCR2\] signaling in liver fibrosis has been established in several experimental models using CCL2- or CCR2-deficient mice. The functional relevance of CCL2 is dependent on the recruitment of HSCs and infiltration of macrophages \[[@pbio.3000563.ref007]--[@pbio.3000563.ref010]\]. Another critical chemokine pathway is the CCL5 (also known as regulated upon activation normal T cell expressed and secreted factor \[RANTES\])-CCR1/CCR5 pathway, which is largely enhanced in fibrotic livers \[[@pbio.3000563.ref011]\]. Either genetic knockout of CCL5 or pharmacological inhibition of CCL5 by the antagonist Met-CCL5 (CCL5 protein Ser24-Ser91, with an N-terminal Met) in mice ameliorated experimental liver fibrosis \[[@pbio.3000563.ref012]\]. In addition, CXCL10 seems profibrogenic, either by modulating hepatic macrophage infiltration or by inhibiting natural killer (NK) cell--mediated HSC inactivation \[[@pbio.3000563.ref013], [@pbio.3000563.ref014]\]. Although the downstream effects of these chemokines are well defined, the associated upstream signaling and transcriptional regulation in hepatocytes remain largely unknown.

Mediator is a transcriptional cofactor complex that is considered as part of the general transcriptional machinery. In response to environmental or developmental cues, Mediator can activate or repress specific gene transcription through physically interacting with distinctive DNA-bound transcription factors (TFs) \[[@pbio.3000563.ref015], [@pbio.3000563.ref016]\]. Increasing evidence suggests that different Mediator subunits control diverse signaling pathways and biological processes; and its dysregulation leads to developmental abnormalities, metabolic disorders, and cancer \[[@pbio.3000563.ref017]\]. In this study, we focused on Mediator complex subunit 23 (MED23), which has been shown to participate in hepatic glucose and lipid metabolism \[[@pbio.3000563.ref018]\]. Although mice with liver-specific knockout of *Med23* (*med23*^Δli^) do not display abnormal hepatic histology and function, *Med23* ablation improves hepatic glucose metabolism, as reflected by enhanced glucose tolerance and insulin sensitivity. Notably, liver-specific *Med23* deletion prevented high-fat diet (HFD)- and genetic-induced obesity and reduced the related pathological consequences of this condition \[[@pbio.3000563.ref018]\]. The spectrum of liver diseases could range from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer \[[@pbio.3000563.ref019]\]. Considering the connection between liver metabolism and chronic liver diseases, we sought to determine whether MED23 might be involved in the pathogenesis of liver fibrosis, and we found that the silencing of *Med23* in hepatocytes aggravates the development of carbon tetrachloride (CCl~4~)-induced hepatic inflammation and fibrosis, thus defining an important role of hepatic MED23 in liver fibrosis. We further unraveled a novel molecular mechanism by which hepatic MED23 negatively regulates the expression of the hepatic chemokines CCL5 and CXCL10 via suppressing the activity of RAR-related orphan receptor alpha (RORα). RORα has been shown in previous studies to be involved in cerebellum development, circadian rhythms, lipid metabolism, and fat accumulation \[[@pbio.3000563.ref020]--[@pbio.3000563.ref024]\]. Our study demonstrated that hepatic RORα, in cooperation with MED23, plays a role in inflammatory responses, acting as a positive regulator of CCL5 and CXCL10 in initiating the liver fibrosis, which suggests new molecular targets for clinical intervention in liver fibrosis.

Results {#sec002}
=======

Mice with hepatocyte-specific *Med23* ablation exhibit enhanced liver fibrosis {#sec003}
------------------------------------------------------------------------------

To investigate the role of MED23 in liver fibrosis, we employed the well-established CCl~4~-induced mouse model of liver fibrosis \[[@pbio.3000563.ref025]\], in which the control *med23-*floxed (*med23*^f/f^) mice and mice with hepatocyte-specific *Med23* deletion (*med23*^Δli^) \[[@pbio.3000563.ref018]\] were intraperitoneally injected with CCl~4~ every 3 days for 1 month. After chronic administration of CCl~4~, *med23*^Δli^ mouse livers exhibited augmented collagen deposition and activated HSC (myofibroblast) expansion compared with these characteristics in *med23*^f/f^ mouse livers, reflected by the increases in Sirius red--positive areas and alpha-smooth muscle actin (α-SMA)-positive areas ([Fig 1A and 1B](#pbio.3000563.g001){ref-type="fig"}). Increased α-SMA expression in *med23*^Δli^ mice was further confirmed by immunoblotting and quantitative real-time PCR (qRT-PCR) of whole-liver homogenates (*Acta2* encodes α-SMA) ([Fig 1C and 1D](#pbio.3000563.g001){ref-type="fig"}).

![Analysis of liver fibrosis in *med23*^f/f^ and *med23*^Δli^ mice after chronic administration of CCl~4~.\
(A) Histology analysis of livers from *med23*^f/f^ and *med23*^Δli^ mice. The liver sections of *med23*^f/f^ and *med23*^Δli^ mice after chronic CCl~4~ administration were stained with Sirius red and α-SMA. Representative pictures were shown. (B) Quantification of Sirius red--positive (*n =* 5 per group) and α-SMA-positive areas (*n =* 7 per group) in the liver sections of *med23*^f/f^ and *med23*^Δli^ mice. (C) The total protein was extracted from whole livers of *med23*^f/f^ and *med23*^Δli^ mice and analyzed by western blotting using the indicated antibodies. GAPDH was used as a loading control. (D-F) The total RNA was extracted from whole livers of *med23*^f/f^ and *med23*^Δli^ mice and then analyzed by qRT-PCR to detect the expression of the liver fibrosis-associated genes. The expression was normalized to *Gapdh* (*n =* 7 per group). Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. α-SMA, alpha-smooth muscle actin; CCl~4~, carbon tetrachloride; Col, collagen; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; *med23*, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; Mmp, matrix metalloproteinase; Pdgfβ, platelet derived growth factor beta; Pdgfrβ, platelet-derived growth factor receptor beta; qRT-PCR, quantitative real-time PCR; Tgfβ1, transforming growth factor beta 1; Tgfβr1, transforming growth factor beta receptor 1; Timp, tissue inhibitor of metalloproteinase.](pbio.3000563.g001){#pbio.3000563.g001}

Additionally, the expression of *Desmin*, a marker of HSCs reflecting the number of HSCs, was also higher in *med23*^Δli^ mouse livers than in *med23*^f/f^ mouse livers ([Fig 1D](#pbio.3000563.g001){ref-type="fig"}). Consistent with the augmented collagen deposition, the collagen type I alpha 1 chain (*Col1a1*) and collagen type III alpha 1 chain (*Col3a1*) levels were up-regulated after *Med23* ablation in hepatocytes ([Fig 1D](#pbio.3000563.g001){ref-type="fig"}). As liver fibrosis is accompanied by dynamic ECM remodeling \[[@pbio.3000563.ref001]\], we further found that the transcription of matrix metalloproteinases (MMPs) and MMP inhibitors (tissue inhibitors of metalloproteinases \[TIMPs\]), including *Mmp9*, *Mmp13*, *Timp1*, and *Timp2*, were higher in *med23*^Δli^ mouse livers than in control mouse livers ([Fig 1E](#pbio.3000563.g001){ref-type="fig"}). In agreement with the increased exacerbation of liver fibrosis, the mRNA levels of profibrogenic factors such as transforming growth factor beta 1 (*Tgfβ1*) and platelet derived growth factor beta (*Pdgfβ*) and their receptors were significantly higher in *med23*^Δli^ mouse livers than in *med23*^f/f^ mouse livers ([Fig 1F](#pbio.3000563.g001){ref-type="fig"}). Collectively, these data suggest that the ablation of *Med23* in hepatocytes renders mice prone to liver fibrosis.

We also examined the effect of hepatic *Med23* deficiency in another NASH model, which used a methionine and choline-deficient (MCD) diet to induce liver pathology including steatosis, liver inflammation and fibrosis, and hepatocyte death (Wang and colleagues, 2016). Similar to the CCl~4~-induced fibrosis model, *Med23* silencing also resulted in increasing mRNAs related to liver fibrosis, including *Col1a1*, *Col3a1*, *Tgfβ1*, *Pdgfβ*, *Tgfβr1*, *Pdgfrβ*, and *Timp1* ([S1A Fig](#pbio.3000563.s001){ref-type="supplementary-material"}). Importantly we observed that there was an increase in α-SMA^+^ cells ([S1B and S1C Fig](#pbio.3000563.s001){ref-type="supplementary-material"}) as well as protein level of Col1a1 in *Med23*-deficient mouse livers ([S1D and S1E Fig](#pbio.3000563.s001){ref-type="supplementary-material"}), suggesting that *Med23* ablation can also promote MCD diet--induced liver fibrosis.

*Med23*^Δli^ mice display enhanced hepatocyte proliferation after the chronic administration of CCl~4~ {#sec004}
------------------------------------------------------------------------------------------------------

Liver fibrosis is generally considered the consequence of wound responses accompanied by hepatocyte proliferation shortly after injury-induced cell death \[[@pbio.3000563.ref003]\]. Therefore, we next examined cell death and proliferation in *med23*^f/f^ and *med23*^Δli^ mouse livers after CCl~4~ exposure. TUNEL staining revealed fewer apoptotic cells in *med23*^Δli^ mouse livers than in control mouse livers ([Fig 2A and 2B](#pbio.3000563.g002){ref-type="fig"}). Consistent with this result, the expression of the antiapoptotic genes cellular inhibitor of apoptosis protein 1 (*cIAP1*) and cellular inhibitor of apoptosis protein 2 (*cIAP2*) was slightly increased in livers with *Med23* deletion compared with that in control livers ([Fig 2C](#pbio.3000563.g002){ref-type="fig"}). Interestingly, we noticed that the apoptotic cells were generally localized with the α-SMA-positive areas in both experimental groups ([Fig 2A](#pbio.3000563.g002){ref-type="fig"}), suggesting that the observed dead cells were mainly HSCs and that the increased myofibroblast numbers in *med23*^Δli^ mouse livers could be the consequence of decreased cell death. In addition, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) secretion by damaged hepatocytes, as well as albumin production, were equal in the experimental groups ([S2A Fig](#pbio.3000563.s002){ref-type="supplementary-material"}), suggesting that the degree of liver injury was similar. The liver weight was slightly decreased in *med23*^Δli^ mice, whereas the liver/body weights of *med23*^Δli^ mice were comparable to those of *med23*^f/f^ mice after chronic CCl~4~ administration ([S2B Fig](#pbio.3000563.s002){ref-type="supplementary-material"}). Noticeably, there was a dramatic increase in hepatocyte proliferation after *Med23* ablation, as evidenced by the increased number of proliferating cell nuclear antigen (PCNA)-positive hepatocytes compared with that in control mice ([Fig 2D](#pbio.3000563.g002){ref-type="fig"}). Consistently, qRT-PCR analysis of mRNA from whole-liver homogenates demonstrated that the level of hepatocyte growth factor (*Hgf*), a key extracellular factor for hepatocyte growth, was higher in *med23*^Δli^ livers than in control livers ([Fig 2E](#pbio.3000563.g002){ref-type="fig"}). Moreover, compared with *med23*^f/f^ mice, *med23*^Δli^ mice exhibited a significant increase in the expression of genes associated with cell proliferation, including *Cyclin D1*, *c-Fos*, and *c-Jun* ([Fig 2E](#pbio.3000563.g002){ref-type="fig"}). Taken together, these results indicate that *med23*^Δli^ mice have improved resistance to CCl~4~-induced hepatic cell death, which may explain the enhanced fibrosis. In addition, *med23*^Δli^ mouse livers displayed greater hepatocyte proliferation than control mouse livers, implying an improvement in the repair capability.

![Reduced liver cell death and enhanced hepatocyte proliferation in *med23*^Δli^ mice after chronic administration of CCl~4~.\
(A) Representative views of TUNEL staining and α-SMA staining in the liver sections of *med23*^f/f^ and *med23*^Δli^ mice. (B) Quantification of TUNEL-positive cells from the liver sections of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n =* 6; *med23*^Δli^, *n =* 7). (C) The expression of antiapoptotic genes (*cIAP1* and *cIAP2)* in whole-liver extracts was analyzed by qRT-PCR (*n =* 7 per group). (D) Representative views and quantification of PCNA staining in the liver sections of *med23*^f/f^ and *med23*^Δli^ mice (*n =* 7 per group). (E) qRT-PCR analysis of proliferative genes (*Hgf*, *CyclinD1*, *c-Fos*, and *c-Jun*) in whole-liver extracts of *med23*^f/f^ and *med23*^Δli^ mice (*n =* 7 per group). Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. α-SMA, alpha-smooth muscle actin; CCl~4~, carbon tetrachloride; cIAP, cellular inhibitor of apoptosis protein; Hgf, hepatocyte growth factor; *med23*, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; PCNA, proliferating cell nuclear antigen; qRT-PCR, quantitative real-time PCR.](pbio.3000563.g002){#pbio.3000563.g002}

Inflammatory infiltration is increased in *med23*^Δli^ mice compared with that in controls after chronic administration of CCl~4~ {#sec005}
---------------------------------------------------------------------------------------------------------------------------------

The infiltration of numerous immune cell populations, including monocytes/macrophages and T cells \[[@pbio.3000563.ref002]\], into the liver is a crucial pathogenic feature following acute and chronic liver injury. Therefore, we next sought to analyze the differential immune responses in the liver between the experimental groups. Histological analysis showed a clear increase in immune cell infiltration ([Fig 3A](#pbio.3000563.g003){ref-type="fig"}), which was further confirmed by the increased expression of the pan-leukocyte markers *Cd45* and *Cd3g* ([Fig 3C](#pbio.3000563.g003){ref-type="fig"}) in *med23*^Δli^ mice compared with that in control mice after chronic CCl~4~ treatment. Specifically, we found that the population of macrophages in the liver, as indicated by immunostaining and qRT-PCR analysis of F4/80 expression, was strikingly increased in *Med23*-deficient livers compared with that in control livers ([Fig 3A--3C](#pbio.3000563.g003){ref-type="fig"}). We further analyzed hepatic mRNA expression of proinflammatory cytokines and chemokines that are responsible for guiding the migration of various immune cells. Whereas the hepatic tumor necrosis factor alpha (*Tnfα*) and interleukin 6 (*Il-6*) mRNA levels were comparable between the experimental groups, the levels of *Il-1α* and *Il-1β* were dramatically increased in *med23*^Δli^ mice compared with those in *med23*^f/f^ mice ([Fig 3D](#pbio.3000563.g003){ref-type="fig"}). Furthermore, we observed increases of at least 1.5-fold in the levels of chemokines, including *Ccl2*, *Ccl4*, *Ccl5*, and *Cxcl10*, as well as the levels of chemokine receptors, including *Ccr1*, *Ccr2*, *Ccr5*, and C-X-C motif chemokine receptor 2 (*Cxcr2*), in *med23*^Δli^ mice relative to these levels in *med23*^f/f^ mice ([Fig 3E and 3F](#pbio.3000563.g003){ref-type="fig"}). Thus, mice with *Med23* deletion in hepatocytes seem to be able to mount augmented immune responses to chronic CCl~4~ administration, which possibly results in enhanced liver fibrosis and increased compensatory hepatocyte proliferation.

![Increased inflammatory infiltration in *med23*^Δli^ mice after the chronic administration of CCl~4~.\
(A) Liver sections from *med23*^f/f^ and *med23*^Δli^ mice were stained with HE, F4/80, and DAPI respectively. (B) Quantification of F4/80-positive cells from the liver sections of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n =* 5; *med23*^Δli^, *n =* 7). (C) The mRNA expression of immune cells markers (*F4/80*, *Cd45*, and *Cd3g)* in whole-liver extracts was analyzed by qRT-PCR (*n =* 7 per group). (D-F) qRT-PCR analysis of the expression of cytokines, chemokines, and their receptors in the liver (*n =* 7 per group). Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. Ccl, C-C motif chemokine ligand; CCl~4~, carbon tetrachloride; Ccr, C-C motif chemokine receptor; Cxcl, C-X-C motif chemokine ligand; Cxcr, C-X-C motif chemokine receptor; HE, hematoxylin--eosin; Il, interleukin; *med23*, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; qRT-PCR, quantitative real-time PCR; *Tnfα*, tumor necrosis factor alpha.](pbio.3000563.g003){#pbio.3000563.g003}

*Med23* deletion enhances the secretion of proinflammatory cytokines and chemokines after acute CCl~4~ treatment {#sec006}
----------------------------------------------------------------------------------------------------------------

To further address the causal associations among the Mediator subunit MED23 expression, proinflammatory factors production, and macrophage infiltration, we characterized the acute (24-hour) response to CCl~4~ administration in *med23*^f/f^ and *med23*^Δli^ mouse livers. It is known that CCl~4~-induced hepatotoxicity is characterized by centrilobular necrosis \[[@pbio.3000563.ref026]\]. Substantial necrosis was observed in control livers by hematoxylin--eosin (HE) staining (Figs [4A](#pbio.3000563.g004){ref-type="fig"} and [S3A](#pbio.3000563.s003){ref-type="supplementary-material"}), but necrosis was scarcely detected in *med23*^Δli^ livers at 24 hours after injury (Figs [4A](#pbio.3000563.g004){ref-type="fig"} and [S3A](#pbio.3000563.s003){ref-type="supplementary-material"}). Consistent with the results of chronic CCl~4~ treatment, TUNEL staining showed much fewer apoptotic cells in acutely injured *med23*^Δli^ mouse livers than in *med23*^f/f^ mouse livers ([Fig 4A and 4B](#pbio.3000563.g004){ref-type="fig"}); this result was verified by the decreased levels of serum ALT and AST ([S3B Fig](#pbio.3000563.s003){ref-type="supplementary-material"}) as well as cleaved caspase 3 and phosphorylation of the histone variant H2AX (γ-H2AX) on immunoblots of whole-liver protein extracts ([Fig 4C](#pbio.3000563.g004){ref-type="fig"}), suggesting that *Med23* ablation may render the liver refractory to the CCl~4~-induced hepatic damage. Although acute CCl~4~ treatment for 24 hours was not able to induce hepatocyte proliferation, as evidenced by the very small numbers of Ki67-positive hepatocytes in control mice, we did observe a small number of proliferative hepatocytes in *med23*^Δli^ mice ([Fig 4D and 4E](#pbio.3000563.g004){ref-type="fig"}). Moreover, qRT-PCR analysis of whole-liver homogenates indicated elevated expression of the proliferation-promoting gene *c-Myc* in *med23*^Δli^ mice compared with that in control mice ([Fig 4F](#pbio.3000563.g004){ref-type="fig"}). These data suggest that liver-specific ablation of the Mediator subunit *Med23* gene resulted in reduced liver damage and enhanced compensatory hepatocyte proliferation in response to acute CCl~4~ treatment.

![More proinflammatory cytokine and chemokine secretion after acute administration of CCl~4~.\
(A) Representative views of HE, TUNEL, and DAPI staining in the liver sections of *med23*^f/f^ and *med23*^Δli^ mice after acute CCl~4~ administration for 24 hours. (B) Quantification of TUNEL-positive cells from the liver sections of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n* = 6; *med23*^Δli^, *n* = 5). (C) The total protein was extracted from whole livers of *med23*^f/f^ and *med23*^Δli^ mice and analyzed by western blotting using the indicated antibodies. GAPDH was used as a loading control. (D, E) Representative views of Ki67 staining (D) and quantification (E) in the liver sections of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n* = 5; *med23*^Δli^, *n* = 4). (F) qRT-PCR analysis of *c-Myc* in whole-liver extracts of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n* = 6; *med23*^Δli^, *n* = 5). (G, H) qRT-PCR analysis of cytokines and chemokines in whole-liver extracts of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n* = 6; *med23*^Δli^, *n* = 5). Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. γ-H2AX, phosphorylation of the histone variant H2AX; Ccl, C-C motif chemokine ligand; CCl~4~, carbon tetrachloride; Cxcl, C-X-C motif chemokine ligand; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HE, hematoxylin--eosin; Il, interleukin; *med23*, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; qRT-PCR, quantitative real-time PCR; *Tnfα*, tumor necrosis factor alpha.](pbio.3000563.g004){#pbio.3000563.g004}

We next performed α-SMA and F4/80 immunostaining as well as a qRT-PCR assay to determine the number of activated HSCs and macrophages, respectively. In contrast to our findings for chronic CCl~4~ treatment, we failed to detect a difference in the numbers of activated HSCs and macrophages between acutely injured control mice and *med23*^Δli^ mice ([S3C--S3F Fig](#pbio.3000563.s003){ref-type="supplementary-material"}). However, we did observe higher mRNA transcript levels of proinflammatory cytokines, including *Tnfα*, *Il-6*, and *Il-1β*, as well as chemokines, including *Ccl2*, *Ccl3*, *Ccl4*, *Ccl5*, *Ccl7*, and *Cxcl10*, in acutely injured *med23*^Δli^ mice than in control mice ([Fig 4G and 4H](#pbio.3000563.g004){ref-type="fig"}), suggesting that these increased cytokines/chemokines in *med23*^Δli^ livers may be not produced by macrophages and HSCs, because the numbers of both of these cell types did not differ between control and *med23*^Δli^ livers after 24 hours of CCl~4~ treatment. Specifically, the protein level of CCL2, which is important for monocyte chemotaxis, was also higher in *med23*^Δli^ mice than in control mice ([S3G Fig](#pbio.3000563.s003){ref-type="supplementary-material"}). By contrast, there was no significant change in the expression of the profibrogenic factors *Tgfβ1* and *Pdgfβ* or the fibrogenic factors *Col1a1* and *Col3a1* between the experimental groups at this early time point ([S3H Fig](#pbio.3000563.s003){ref-type="supplementary-material"}). Thus, it seems that hepatocyte-specific deletion of *Med23* leads to increased secretion of proinflammatory cytokines and chemokines initially, which may subsequently facilitate macrophage and leukocyte recruitment as well as HSC activation.

Hepatic MED23 suppresses *Ccl5* and *Cxcl10* expression in vivo and in vitro {#sec007}
----------------------------------------------------------------------------

Hepatic macrophages are well characterized as a main source of proinflammatory factors that contribute to liver fibrosis \[[@pbio.3000563.ref002]\]. However, hepatocytes have also been suggested to produce proinflammatory factors during the process of liver fibrosis \[[@pbio.3000563.ref027]\]. Because it is not clear whether the increased inflammatory factors are derived from the *Med23*-deficient hepatocytes or the infiltrated immune cells, we depleted liver macrophages by tail vein injection of clodronate liposomes ([Fig 5A](#pbio.3000563.g005){ref-type="fig"}), as reported \[[@pbio.3000563.ref028], [@pbio.3000563.ref029]\]. Indeed, compared with injection of control liposomes, injection of clodronate liposomes into *med23*^Δli^ mice resulted in an evident reduction in macrophage numbers, as indicated by the expression of the surface marker F4/80, and it did not affect the efficiency of *Med23* deletion ([Fig 5B and 5C](#pbio.3000563.g005){ref-type="fig"}). Clodronate administration also abolished the marked increase in the production of some cytokines and chemokines, including *Tnfα*, *Il-6*, *Il-1α*, *Il-1β*, and *Ccl2*, in *Med23*-deficient livers under acute CCl~4~ treatment ([Fig 5D](#pbio.3000563.g005){ref-type="fig"}), suggesting that macrophages may be the source of these increased inflammatory factors. However, *Ccl5* and *Cxcl10* expression remained higher in *med23*^Δli^ mice than in control mice after injection with clodronate liposomes ([Fig 5D](#pbio.3000563.g005){ref-type="fig"}), suggesting that the increased levels of these two important chemokines could be produced by hepatocytes instead of macrophages.

![Increased *Ccl5* and *Cxcl10* expression directly in hepatocytes with *Med23* deletion in vivo and in vitro.\
(A) Strategy to delete macrophages in liver and administrate with acute CCl~4~ for 24 hours. (B) Representative views of F4/80 staining in the liver sections of *med23*^f/f^ and *med23*^Δli^ mice after tail intravenous injection of control liposome and clodronate liposome and then CCl~4~ administration for 24 hours. (C) qRT-PCR analysis of *Med23* and *F4/80* in whole-liver extracts of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^-Control, *n* = 4; *med23*^Δli^-Control, *n* = 4; *med23*^Δli^-Clodronate, *n* = 7). (D, E) qRT-PCR analysis of proinflammatory cytokines and chemokines in whole-liver extracts of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^-Control, *n* = 4; *med23*^Δli^-Control, *n* = 4; *med23*^Δli^-Clodronate, *n* = 7) (D) and AML12 cells with *Med23* knockdown (*n* = 3 per group) (E). (F) The protein level of MED23 was analyzed by western blotting in AML12 cells after CRISPR/Cas9 mediated *Med23* KO. GAPDH was used as a loading control. (G) qRT-PCR analysis of *Ccl5* and *Cxcl10* in *Med23* KO AML12 cells (*n* = 3 per group). (H, I) qRT-PCR analysis of proinflammatory cytokines and chemokines in AML12 cells after transient transfection (*n* = 3 per group). Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. AML12, alpha mouse liver 12; Ccl, C-C motif chemokine ligand; CCl~4~, carbon tetrachloride; Cxcl, C-X-C motif chemokine ligand; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Il, interleukin; KO, knockout; MED23, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; qRT-PCR, quantitative real-time PCR; shCtrl, negative control vector containing scrambled shRNA; shMed23, shRNA against Med23; *Tnfα*, tumor necrosis factor alpha; WT, wild-type.](pbio.3000563.g005){#pbio.3000563.g005}

These phenomena seemed to be cell autonomous because *Med23* knockdown dramatically enhanced the transcriptional levels of some proinflammatory factors, especially *Ccl5* and *Cxcl10*, in alpha mouse liver 12 (AML12) immortalized mouse hepatocytes ([Fig 5E](#pbio.3000563.g005){ref-type="fig"}). These regulatory effects were confirmed in *Med23*-knockout AML12 cells created by clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) ([Fig 5F and 5G](#pbio.3000563.g005){ref-type="fig"}). We further tested the inhibitory role of the Mediator subunit MED23 in transient transfection assays; surprisingly, increasing amounts of *Med23* overexpression increased the mRNA level of *Ccl5* and *Cxcl10* in a dose-dependent manner ([Fig 5H](#pbio.3000563.g005){ref-type="fig"}), but did not affect the expression levels of *Tnfα* or *Ccl2*, which are independent of hepatic MED23 expression ([Fig 5H](#pbio.3000563.g005){ref-type="fig"}). By contrast, overexpression of another Mediator subunit, MED24, did not greatly change the expression of *Ccl5* or *Cxcl10* ([Fig 5I](#pbio.3000563.g005){ref-type="fig"}), underscoring the specific effect of MED23 on *Ccl5* and *Cxcl10* expression. A previous study proposed that *Med23* overexpression could inhibit transcriptional activation through sequestering the whole Mediator complex from the transcriptional machinery \[[@pbio.3000563.ref030]\]. Here, it seems that the overexpressed MED23 is able to sequester the whole Mediator complex, thus counteracting the inhibitory effect of the Mediator complex on *Ccl5* and *Cxcl10* expression.

Hepatocyte MED23 cooperates with RORα to regulate *Ccl5* and *Cxcl10* expression {#sec008}
--------------------------------------------------------------------------------

To better understand the mechanisms through which *Med23* deficiency enhances *Ccl5* and *Cxcl10* expression in hepatocytes, we carried out a genome-wide transcriptome analysis of whole livers from control and *med23*^Δli^ mice 24 hours after CCl~4~ treatment. RNA-seq data analysis revealed that 593 genes were down-regulated more than 2-fold and 660 genes were up-regulated more than 2-fold in the *med23*^Δli^ set relative to their expression in the control set ([Fig 6A](#pbio.3000563.g006){ref-type="fig"}). Gene set enrichment analysis (GSEA) of these up-regulated genes showed that they were enriched in monocyte chemotaxis, consistent with the effect of *Med23* deletion in up-regulating the expression of various chemokines ([Fig 6B and 6C](#pbio.3000563.g006){ref-type="fig"}).

![Hepatocyte MED23 cooperates with RORα to regulate *Ccl5* and *Cxcl10*.\
(A) Heatmap analysis of differential expression genes between *med23*^f/f^ and *med23*^Δli^ mouse livers after acute administration of CCl~4~ for 24 hours. We found that 593 genes were down-regulated (\>2-fold) and 660 genes were up-regulated (\>2-fold) in the *med23*^Δli^ mice. (B-C) GSEA analysis of up-regulated genes (\>2-fold) in *med23*^Δli^ mice (B) and genes included in the panel B (C). (D) IPA was performed to predict the upstream regulator of up-regulated genes (\>2-fold). The top five regulators are listed. (E) qRT-PCR analysis of *RORα*, *Ccl5*, and *Cxcl10* expression in AML12 cells after *RORα* knockdown (*n* = 3 per group). (F) Western blotting analysis of CXCL10 protein expression in AML12 cells after *RORα* knockdown. GAPDH was used as a loading control. (G) Effect of *RORα* overexpression on RORE and Ccl5-pro luciferase reporter activity in AML12 cells (*n* = 3 per group). (H) qRT-PCR analysis of *Ccl5* and *Cxcl10* expression in AML12 cells after *RORα* overexpression (*n* = 4 per group). (I) qRT-PCR analysis of *Ccl5* and *Cxcl10* expression in shCtrl and shMed23 AML12 cells after *RORα* knockdown. The expression was normalized to *Gapdh* (*n* = 3 per group). (J, K) Effect of MED23 on RORE-luciferase reporter activity in HeLa cell line (*n* = 3 per group). Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. AML12, alpha mouse liver 12; Ccl, C-C motif chemokine ligand; CCl~4~, carbon tetrachloride; CEBPB, CCAAT enhancer binding protein beta; Cxcl, C-X-C motif chemokine ligand; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluorescent protein; GSEA, gene set enrichment analysis; IPA, Ingenuity Pathway Analysis; KO, knockout; MED23, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; PPARα, peroxisome proliferator activated receptor alpha; qRT-PCR, quantitative real-time PCR; RORα, RAR-related orphan receptor alpha; RORE, RORα response element; shCtrl, negative control vector containing scrambled shRNA; shMed23, shRNA against Med23; siCtrl, negative control vector containing scrambled siRNA; siRORα, siRNA against RORα; TNFα, tumor necrosis factor alpha; WT, wild-type.](pbio.3000563.g006){#pbio.3000563.g006}

Mediator is known as a transcriptional cofactor targeted by distinct TFs in response to different signaling stimulators \[[@pbio.3000563.ref015]\]. To identify the potential TFs cooperating with MED23 to control the expression of various chemokines, we then performed Ingenuity Pathway Analysis (IPA) on significantly up-regulated genes with a 2-fold increase in expression after *Med23* deletion in hepatocytes. The predicted upstream regulators pointed toward several TFs, including RORα, CCAAT enhancer binding protein beta (C/EBPβ), RORγ, and peroxisome proliferator activated receptor alpha (PPARα), possibly activated after *Med23* ablation in hepatocytes ([Fig 6D](#pbio.3000563.g006){ref-type="fig"}), implying that these genes could contribute to the increased chemokine expression. Analysis of the published database revealed higher *RORα* expression in cirrhosis samples than in normal samples, whereas the expression of other TFs was unchanged ([S4A Fig](#pbio.3000563.s004){ref-type="supplementary-material"}); therefore, we focused on further analysis of RORα. To verify that RORα regulates *Ccl5* and *Cxcl10* expression, we knocked down *Rorα* in wild-type (WT) AML12 cells using small interfering RNA (siRNA) and observed that the *Ccl5* and *Cxcl10* mRNA levels were consistently decreased after RNA interference (RNAi) transfection ([Fig 6E](#pbio.3000563.g006){ref-type="fig"}). The protein level of CXCL10 was much lower in *Rorα*-silenced AML12 cells than in control cells ([Fig 6F](#pbio.3000563.g006){ref-type="fig"}). We further introduced *RORα* into the WT AML12 cells using retroviral transduction and found that ectopic *RORα* expression indeed activated RORα response element (RORE) reporter activity (Figs [6G](#pbio.3000563.g006){ref-type="fig"} and [S4B](#pbio.3000563.s004){ref-type="supplementary-material"}). qRT-PCR and luciferase reporter results revealed that ectopic expression of *RORα* strongly stimulated *Ccl5* expression and modestly increased *Cxcl10* expression ([Fig 6G and 6H](#pbio.3000563.g006){ref-type="fig"}) but had no effect on *Ccl2* transcription level ([S4C Fig](#pbio.3000563.s004){ref-type="supplementary-material"}). These data suggested that RORα is a novel upstream regulator of *Ccl5* and *Cxcl10*. To further understand how MED23 cooperates with RORα to regulate *Ccl5* and *Cxcl10* expression, *Rorα* was knocked down in AML12 cells with or without *Med23* knockdown. Notably, the increase in the levels of *Ccl5* and *Cxcl10* mRNA by *Med23* deficiency was significantly reduced after *Rorα* knockdown ([Fig 6I](#pbio.3000563.g006){ref-type="fig"}), suggesting a possible functional interaction between RORα and MED23 in controlling *Ccl5* and *Cxcl10* expression but not *Ccl2* expression ([S4D Fig](#pbio.3000563.s004){ref-type="supplementary-material"}).

We next performed dual-luciferase reporter assays to assess the effect of MED23 on RORα-driven RORE reporter activity. Consistent with endogenous *Ccl5* and *Cxcl10* regulation, *MED23* deletion significantly increased the RORE reporter activity driven by RORα ([Fig 6J](#pbio.3000563.g006){ref-type="fig"}). Moreover, we transfected HeLa cells with increasing dosage of *RORα* and *Med23* along with RORE reporter to further verify the regulation of RORα activity by MED23. Increasing RORα expression up-regulates the RORE reporter activity in a dose-dependent manner ([Fig 6K](#pbio.3000563.g006){ref-type="fig"}). Importantly, RORα-activated RORE activity was repressed gradually with increasing dosage of *Med23* (up to 2-fold decrease) ([Fig 6K](#pbio.3000563.g006){ref-type="fig"}). Together, these data suggested that the Mediator subunit MED23 could act as a "corepressor" of RORα in directing *Ccl5* and *Cxcl10* transcription.

Mediator is well recognized as a coactivator for transcriptional activation; however, there are a few studies showing that several Mediator subunits, especially the kinase submodule, may also inhibit gene transcription \[[@pbio.3000563.ref031]--[@pbio.3000563.ref033]\]. For example, Mediator has been shown to link the RE1 silencing TF (REST) with the G9a histone methyltransferase to suppress neuronal gene expression through histone H3K9 dimethylation in nonneuronal cells \[[@pbio.3000563.ref031], [@pbio.3000563.ref034]\]. To dissect how the Mediator subunit MED23 suppresses cytokine gene expression, we performed chromatin immunoprecipitation (ChIP) assays and found that the binding pattern of MED23 and RNA polymerase II (Pol II) at the promoter regions (P1, P2, and P3) of *Ccl5* and *Cxcl10* were similar; importantly, the occupancy of MED23 is most enriched at the core promoter regions (P1 and P2) ([Fig 7A](#pbio.3000563.g007){ref-type="fig"}). Interestingly we also observed the occupancy of MED23 in the *Ccl5* coding region (P4), implying that MED23 might also affect *Ccl5* expression via the postrecruitment function ([Fig 7A](#pbio.3000563.g007){ref-type="fig"}). We further analyzed the histone methylation profiles of the *Ccl5* and *Cxcl10* gene promoters in *med23*^f/f^ and *med23*^Δli^ mouse liver tissues and observed high H3K9 dimethylation occupancy in the proximal and distal promoters of *Ccl5* and *Cxcl10*, which was largely reduced in livers with *Med23* deletion ([Fig 7B](#pbio.3000563.g007){ref-type="fig"}). In comparison, the H3K4 trimethylation occupancy in the *Ccl5* and *Cxcl10* promoters was comparable between *med23*^f/f^ and *med23*^Δli^ mouse livers ([Fig 7B](#pbio.3000563.g007){ref-type="fig"}). We next examined whether the histone methyltransferase G9a affects *Ccl5* and *Cxcl10* expression and observed that, compared with the vector control, *G9a* overexpression in AML12 cells repressed *Ccl5* and *Cxcl10* mRNA expression, whereas the MED23-independent *Ccl2* mRNA level was not affected by *G9a* overexpression ([Fig 7C](#pbio.3000563.g007){ref-type="fig"}). Together, these data suggest a mechanistic model in which the Mediator subunit MED23 may suppress RORα-directed *Ccl5* and *Cxcl10* expression through G9a-mediated H3K9 dimethylation.

![*Med23* deletion causes decreased H3K9me2 occupancy among the promoter of *Ccl5* and *Cxcl10*.\
(A, B) ChIP analysis of MED23 and Pol II occupancy in AML12 cells (*n* = 3 per group) (A) as well as H3K4me3 and H3K9me2 occupancy in *med23*^f/f^ and *med23*^Δli^ mouse livers after acute administration of CCl~4~ (*med23*^f/f^, *n* = 3; *med23*^Δli^, *n* = 4) (B). IgG was used as a negative control. The precipitated DNA was analyzed by qRT-PCR with primers targeting the promoter regions of *Ccl5* and *Cxcl10*. The relative binding level of each factor was calculated by normalization to the input DNA. (C) qRT-PCR analysis of proinflammatory cytokines and chemokines in AML12 cells after *G9a* transient transfection (*n* = 3 per group). (D) A proposed model for the role of MED23 in hepatocyte after CCl~4~ challenge. MED23 modulates RORα transcriptional activity possibly via G9a-mediated H3K9me2 modification to the target promoters for transcriptional repression. Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. AML12, alpha mouse liver 12; Ccl, C-C motif chemokine ligand; CCl~4~, carbon tetrachloride; ChIP, chromatin immunoprecipitation; Cxcl, C-X-C motif chemokine ligand; IgG, immunoglobulin G; KO, knockout; MED23, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; Pol II, RNA polymerase II; qRT-PCR, quantitative real-time PCR; RORα, RAR-related orphan receptor alpha; WT, wild-type.](pbio.3000563.g007){#pbio.3000563.g007}

Discussion {#sec009}
==========

The hepatic cellular responses to toxic drugs such as CCl~4~ are orchestrated by multiple sophisticated events including the death of hepatocytes, infiltration of immune cells, and reactivation of quiescent HSCs, which ultimately lead to an abnormal architecture and to organ damage and dysfunction \[[@pbio.3000563.ref001]\]. In our efforts to understand the molecular basis of liver fibrosis, we discovered that the Mediator subunit MED23 may act as a transcriptional "brake" for the expression of *Ccl5* and *Cxcl10* in hepatocytes as well as for the subsequent proinflammatory cascades, which curbs CCl~4~-induced HSC activation and liver fibrosis ([Fig 7D](#pbio.3000563.g007){ref-type="fig"}). In summary, the Mediator subunit MED23 is an anti-inflammatory and antifibrogenic factor in the liver.

Several types of cells can be stimulated to express and secrete cytokines/chemokines; in the liver, hepatocytes, macrophages and activated HSCs have been reported to produce and release cytokines/chemokines during the pathogenesis of liver injury and diseases \[[@pbio.3000563.ref002]\]. The functions of these cytokines/chemokines and their receptors in the diseased liver have been established through knockout mouse models \[[@pbio.3000563.ref009]--[@pbio.3000563.ref011], [@pbio.3000563.ref013]\], though their regulation by upstream signaling is not clear. We observed that mice with hepatocyte-specific *Med23* deletion show enhanced liver fibrosis. Consistent with this phenotype, we observed more extensive cytokine/chemokine expression in *med23*^Δli^ mouse livers than in control mouse livers after acute and/or chronic CCl~4~ challenge. Through selective macrophage ablation via clodronate liposome injection and in vitro cell line analysis, we further discovered that among the cytokines/chemokines, CCL5 and CXCL10 appeared to be produced in a manner directly controlled by hepatic MED23, implying that hepatic MED23 functions as a negative upstream regulator of these two important chemokines. Although the hepatocytes are thought not to be the main source of these chemokines (e.g., CCL5 and CXCL10) in the liver under the normal state, some chemokines could be derived from hepatocytes, especially when hepatic homeostasis is disrupted by manipulation like deletion of *Med23* under CCl~4~ treatment. We thus postulate that *Med23*-deficient hepatocytes are prone to induce excessive CCL5 and CXCL10 production at the injury site, which then creates a concentration gradient to attract additional macrophages and HSCs. The activated macrophages and HSCs communicate with each other through secreted factors to form a vicious cycle, which finally leads to augmented fibrosis. Lastly, we could not exclude the possibility at the present time that *Med23* deletion may also trigger the enlarged inflammatory responses via the additional molecular mechanisms, such as that *Med23*-deficient hepatocytes could activate other liver cells to produce the cytokines/chemokines. Overall, our study could expand the molecular network of upstream signaling in the production of chemokines associated with liver fibrosis.

To better understand how hepatocyte MED23 regulates the expression of *Ccl5* and *Cxcl10*, we investigated the upstream TFs that might function through the Mediator subunit MED23. Both the comprehensive transcriptome analysis and in vitro assays indicate that RORα, one member of the ROR family, is the partner of MED23 in the pathogenesis of liver fibrosis. RORα is reported to regulate cerebellum development \[[@pbio.3000563.ref020], [@pbio.3000563.ref035]\] and circadian rhythms \[[@pbio.3000563.ref021], [@pbio.3000563.ref022]\], as well as lipid metabolism and fat accumulation \[[@pbio.3000563.ref023], [@pbio.3000563.ref024], [@pbio.3000563.ref036]\]. However, the role of RORα in impacting inflammatory responses is controversial \[[@pbio.3000563.ref036]--[@pbio.3000563.ref039]\]. RORα negatively regulated the TNFα-induced inflammatory responses in primary aortic smooth-muscle cells by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcriptional activity \[[@pbio.3000563.ref037]\]. In vitro evidence supported the anti-inflammatory function of RORα in human macrophages \[[@pbio.3000563.ref038]\]. By contrast, RORα has also been reported as a proinflammatory factor. RORα overexpression or treatment with the RORα-specific agonist increased the expression of inflammatory cytokines and increased the number of infiltrated macrophages into adipose tissue \[[@pbio.3000563.ref039]\]. Additionally, in the adipose of RORα^sg/sg^ (staggerer \[sg\]) mice fed with an HFD, inflammatory response was significantly reduced \[[@pbio.3000563.ref036]\]. These observations suggest that the influence of RORα on inflammatory responses is cell and tissue dependent. The potential effects of RORα on inflammatory responses in hepatocytes and liver are largely unknown. We found in this study that RORα can act as the upstream TF to specifically control *Ccl5* and *Cxcl10* expression positively in hepatocytes, thereby aggravating the immune response in liver. These observations provide a promising strategy for inhibiting the activation of inflammatory responses by RORα antagonists in liver disease development. Besides, it is worthwhile to note that MED23 may regulate *Ccl5* and *Cxcl10* expression via alternative molecules. For example, C/EBPβ, which determines differential gene activation by interacting with the Mediator MED23 subunit \[[@pbio.3000563.ref040]\], was also predicted to regulate *Ccl5* and *Cxcl10* expression. However, we observed that knockdown of *C/EBPβ* only slightly affected the increase in *Ccl5* and *Cxcl10* expression caused by *Med23* silencing in AML12 cells, suggesting that C/EBPβ may not be the major player in this model system.

We observed that MED23 suppresses the transcriptional activity of RORα in hepatocytes through G9a-mediated H3K9 dimethylation ([Fig 7D](#pbio.3000563.g007){ref-type="fig"}). In a previous study, hepatic RORα was showed to play a pivotal role in maintaining homeostasis of lipid metabolism by regulating PPARγ signaling through recruiting histone deacetylase 3 (HDAC3) to the target genes for transcriptional repression \[[@pbio.3000563.ref024]\]. Interestingly, we have also previously observed that HDAC1 is among the potential interacting protein partners of MED23 \[[@pbio.3000563.ref041]\]. In the future, it will be interesting to define the dynamic interacting protein network with which Mediator MED23 participates in the different diseases and to determine exact molecular mechanisms underlying the liver disease--related transcription regulation.

After chronic liver injury, surviving liver parenchyma cells expand to replenish the surrounding dead cells to maintain homeostasis \[[@pbio.3000563.ref003]\]. However, in our study, although ECM deposition and liver fibrosis increased after hepatocyte-specific *Med23* deletion, we further observed increased compensatory hepatocyte proliferation in *med23*^Δli^ mice compared with that in control mice. These data suggest that *Med23*-deficient hepatocytes display increased regenerative capability after CCl~4~ injury, although the detailed mechanisms remain to be further investigated. Perhaps the cross talk between hepatocytes and nonparenchymal liver cells, such as HSCs and immune cells, contributes to the induction of hepatocyte proliferation; and *Med23* deficiency in hepatocytes results in increased immune cell infiltration and HSC activation while providing additional paracrine signals (HGF, cytokines, chemokines, etc.) to stimulate hepatic proliferation. Conceivably, modulating paracrine signaling may present interesting approaches for liver regeneration or liver cancer treatment.

In conclusion, we demonstrate for the first time that the Mediator subunit MED23 plays an important role in experimental liver fibrosis and provide new insight into the molecular mechanisms of inflammatory responses that initiate fibrotic changes upon liver injury. In the future, targeting the MED23/chemokine axis may provide intervention strategies for liver fibrosis.

Materials and methods {#sec010}
=====================

Ethics statement {#sec011}
----------------

All animal experiments were conducted using mice bred at and maintained in our animal facility according to the guidelines of the Institutional Animal Care and Use Committee of the Shanghai Institute of Biochemistry and Cell Biology (IACUC-PR01).

Animals {#sec012}
-------

The *med23*^f/f^ mice were generated via homologous recombination \[[@pbio.3000563.ref042]\]. *Albumin*-cre mice were a generous gift from Dr. Lijian Hui (Shanghai Institute of Biochemistry and Cell Biology, CAS, China). To generate hepatocyte-specific *med23*^Δli^ mice, *med23*^f/f^ mice were crossbred with *Albumin*-cre mice as described previously \[[@pbio.3000563.ref018]\]. All animals were maintained under a 12-hour light/12-hour dark cycle in specific pathogen--free conditions.

CCl~4~-induced fibrosis model {#sec013}
-----------------------------

The 8-week-old male mice were intraperitoneally injected with 0.6 μl/g body weight CCl~4~ (1:4 vol/vol in sunflower oil from Sigma) every 3 days for 4 weeks to induce liver fibrosis. All mice were euthanized 72 hours after the final CCl~4~ injection, and livers were collected for histological, cytological, biochemical, and molecular analyses. To induce acute liver injury, 8-week-old male mice were injected with CCl~4~ as described above; all animals were euthanized 24 hours after CCl~4~ injection.

Cell culture {#sec014}
------------

The AML12 cell line was kindly provided by Dr. Jianguo Song \[[@pbio.3000563.ref043]\] (Shanghai Institute of Biochemistry and Cell Biology, CAS, China). The 293T and HeLa cell lines were as described previously \[[@pbio.3000563.ref044], [@pbio.3000563.ref045]\]. All cell lines were cultured in DMEM (HyClone, SH30243.01) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco, 15140122) at 37°C with 5% CO~2~.

Histological analysis {#sec015}
---------------------

HE and immunohistochemistry were performed on formalin-fixed paraffin-embedded liver sections as described previously \[[@pbio.3000563.ref046]\]. The following antibodies were used for staining: anti-α-SMA (Abcam, ab124964), anti-PCNA (Cell Signaling Technology, 2586), and anti-Ki67 (Novocastra, NCL-Ki67p).

To detect collagen deposition, paraffin sections were stained with Sirius red dissolved in picric acid solution according to the manufacturer's recommendations.

For F4/80 immunofluorescence staining, liver cryosections were fixed in precooled acetone for 10 minutes and washed with phosphate-buffered saline (PBS) three times. After immersion in diluted normal goat serum, sections were sequentially incubated with anti-mouse F4/80 antigen PE (eBioscience, 12--4801) overnight at 4°C. Nuclei were stained with DAPI for 5 minutes after two washes with PBS.

TUNEL assays were performed using an Apoptosis DNA Fragmentation Assay Kit (Clontech, \#630107) to detect apoptotic cells. All images were visualized using a U-RFL-T microscope (Olympus, Tokyo, Japan). The positive cells or areas were counted or measured in at least five fields on each slide using ImageJ (NIH) software.

Macrophage elimination by clodronate liposomes {#sec016}
----------------------------------------------

A single dose of control liposomes or clodronate liposomes (10 μl/g body weight) was intravenously injected into the tail vein of 8-week-old male mice to deplete macrophages. After 24 hours, the mice were administered a CCl~4~ injection; and after an additional 24 hours, the mice were euthanized, and F4/80 immunofluorescence staining was performed to detect the efficiency of macrophage elimination.

RNA-seq and data analysis {#sec017}
-------------------------

The purity and integrity of the extracted RNA were confirmed using an Agilent Bioanalyzer. Libraries were prepared from 100 ng of total RNA (TruSeq v2, Illumina), and pair-ended sequencing was performed on an Illumina HiSeq 2500 using bar-coded multiplexing and a 150-bp read length, yielding a median of 34.1 M reads per sample. After quality assessment of the corresponding FASTQ files with FastQC, adapter sequences were trimmed from the reads. Read alignment and junction finding were accomplished using TopHat, and differential gene expression was analyzed with Cuffdiff using the University of California Santa Cruz (UCSC) mm10 assembly as the reference sequence. In addition, genes with an expression fold change of \>\|2\| were selected for further analysis (accession code GSE137457).

Construction of stable *Med23* knockdown cells {#sec018}
----------------------------------------------

An AML12 cell line with stable *Med23* knockdown was established according to the manufacturer's recommendation (Clontech). Briefly, retroviruses were generated following the cotransfection of recombinant pSiren-RetroQ plasmids with the pCL10A1 helper plasmid into 293T cells using Lipofectamine 2000 (Invitrogen, 11668019). Culture supernatants containing retroviruses were harvested 48 hours after transfection and filtered through 0.22-μm filters. Virus-containing supernatants were mixed with 4 μg/ml Polybrene (1:100, Sigma-Aldrich) and 10 μM HEPES (pH 7.5, 1:100) and were then added to the plated cells for spin infection (2,500 rpm, 30°C, 90 minutes). Cells were selected with puromycin (Sigma-Aldrich) 24 hours after spin infection. The targeting sequences are listed in [S1 Table](#pbio.3000563.s008){ref-type="supplementary-material"}.

siRNA transfection {#sec019}
------------------

AML12 cells were transfected with the indicated siRNAs (10 μM) using RNAiMax transfection reagent (Invitrogen, 13778150) according to the manufacturer's instructions. At 48 hours after transfection, cells were collected for protein and RNA extraction. For [Fig 6I](#pbio.3000563.g006){ref-type="fig"}, retrovirally mediated *Med23* knockdown or the control AML12 cells were seeded into 6-well plates (150,000 cells per well). The next day, these cells were transfected with the control siRNA or RORα siRNA (10 μM) using RNAiMax transfection reagent. At 48 hours after transfection, cells were collected for protein and RNA extraction. The targeting sequences are listed in [S2 Table](#pbio.3000563.s009){ref-type="supplementary-material"}.

ChIP {#sec020}
----

Mouse livers (0.2 g) for ChIP assays were freshly isolated and cut into small pieces in precooled PBS supplemented with protein inhibitors. After centrifugation (450*g*, 4°C, 5 minutes), the small pieces were cross-linked with a final concentration of 1% formaldehyde in PBS on a shaker for 20 minutes at room temperature and neutralized by the addition of glycine to a final concentration of 0.125 M for 5 minutes. After washing with precooled PBS, the small pieces were homogenized in ChIP lysis buffer (50 mM Tris-HCl, pH 7.4; 1% SDS; and 10 mM EDTA), and the pellet was collected, followed by sonication. The following procedures were performed as described previously \[[@pbio.3000563.ref018]\]. The antibodies used for ChIP were as follows: anti-H3K4me3 (Abcam, ab8580) and anti-H3K9me2 (Abcam, ab1220). DNA extracted from ChIP products was analyzed by qRT-PCR with TB Green Premix Ex Taq (Tli RNaseH Plus) (Takara, RR420A). The primers are listed in [S3 Table](#pbio.3000563.s010){ref-type="supplementary-material"}.

Dual-luciferase reporter assay {#sec021}
------------------------------

The dual-luciferase reporter assay was performed as described \[[@pbio.3000563.ref047]\]. Briefly, HeLa and AML12 cells were seeded into a 12-well plate at 1 × 10^5^ cells per well overnight. These cells were then transfected with a luciferase reporter plasmid and pRL-TK (Promega) along with various expression constructs, as indicated, by Lipofectamine 2000 (Invitrogen, 11668019). All wells were supplemented with control empty expression vector plasmids to keep the total amount of DNA constant. The cells were harvested and subjected to dual-luciferase reporter assays after 24--36 hours of transfection according to the manufacturer's protocol (Promega).

Statistical analysis {#sec022}
--------------------

All data are presented as the means ± SEM. A two-tailed unpaired Student *t* test or Mann-Whitney test was used to determine significant differences between data sets using GraphPad Prism (version 5.0). Differences were considered statistically significant when *P* ≤ 0.05.

Supporting information {#sec023}
======================

###### Analysis of *med23*^f/f^ and *med23*^Δli^ mice livers after feeding with MCD diet.

\(A\) qRT-PCR analysis of fibrosis-related factors in whole-liver extracts of *med23*^f/f^ and *med23*^Δli^ mice fed with a MCD diet (*med23*^f/f^, *n* = 9; *med23*^Δli^, *n* = 6). (B) Liver sections from *med23*^f/f^ and *med23*^Δli^ mice fed with a MCD diet were stained with HE and α-SMA, and representative views are shown. (C) Quantification of the α-SMA-positive area in livers of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n* = 9; *med23*^Δli^, *n* = 6). (D) The total protein was extracted from whole livers of *med23*^f/f^ and *med23*^Δli^ mice fed with a MCD diet and analyzed by western blotting using the indicated antibodies. HSP70 was used as a loading control. (E) Quantification of the α-SMA and Col1a1 levels in livers of *med23*^f/f^ and *med23*^Δli^ mice (by the gray degree value in D) and normalized to the HSP70. Error bars denote SEM from three independent experiments (*med23*^f/f^, *n* = 4; *med23*^Δli^, *n* = 4). Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. α-SMA, alpha-smooth muscle actin; Col, collagen; HE, hematoxylin--eosin; HSP70, hot shock protein 70; MCD, methionine and choline-deficient; *med23*, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; qRT-PCR, quantitative real-time PCR.

(TIF)

###### 

Click here for additional data file.

###### Liver injury and liver/body weight are comparable between *med23*^f/f^ and *med23*^Δli^ mice after chronic CCl~4~ administration (related to [Fig 2](#pbio.3000563.g002){ref-type="fig"}).

\(A\) Serum ALT, AST, and albumin were measured in *med23*^f/f^ and *med23*^Δli^ mice (*n* = 6--7 per group). (B) Analysis of liver weight, body weight, and liver/body weight in *med23*^f/f^ and *med23*^Δli^ mice (*n* = 7 per group). Data are presented as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCl~4~, carbon tetrachloride; *med23*, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed.

(TIF)

###### 

Click here for additional data file.

###### Analysis of *med23*^f/f^ and *med23*^Δli^ mice livers after acute CCl~4~ administration (related to [Fig 4](#pbio.3000563.g004){ref-type="fig"}).

\(A\) Representative views of HE staining in the liver sections of *med23*^f/f^ and *med23*^Δli^ mice after acute CCl~4~ administration for 24 hours. (B) Serum ALT and AST were measured in *med23*^f/f^ and *med23*^Δli^ mice after acute CCl~4~ administration for 24 hours (nontreated: *med23*^f/f^, *n* = 7; *med23*^Δli^, *n* = 7; CCl~4~ 24h: *med23*^f/f^, *n* = 5; *med23*^Δli^, *n* = 4). (C) Representative images of α-SMA and F4/80 staining in the liver sections of *med23*^f/f^ and *med23*^Δli^ mice after acute CCl~4~ administration for 24 hours. The liver paraffin sections were stained with α-SMA antibody, and liver frozen sections were stained with F4/80 antibody (red). DAPI (blue) was used for nuclear counterstaining. (D) Quantification of F4/80-positive cells from the liver sections of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n* = 6; *med23*^Δli^, *n* = 4). (E-F) qRT-PCR analysis of *Acta2* (E) and *F4/80* (F) expression in whole-liver extracts of *med23*^f/f^ and *med23*^Δli^ mice. The mRNA expression was normalized to *Gapdh* (*med23*^f/f^, *n* = 6; *med23*^Δli^, *n* = 5). (G) Western blotting analysis of total protein extracted from whole livers of *med23*^f/f^ and *med23*^Δli^ mice using the indicated antibodies. GAPDH was used as a loading control. (H) qRT-PCR analysis of fibrosis-associated genes expression in whole-liver extracts of *med23*^f/f^ and *med23*^Δli^ mice (*med23*^f/f^, *n* = 6; *med23*^Δli^, *n* = 5). Data are presented as means ± SEM. \*\**P* \< 0.01. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. α-SMA, alpha-smooth muscle actin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCl~4~, carbon tetrachloride; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HE, hematoxylin--eosin; *med23*, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; *med23*^f/f^, *med23-*floxed; qRT-PCR, quantitative real-time PCR.

(TIF)

###### 

Click here for additional data file.

###### Expressional analysis of predicted upstream regulators in liver samples of published database (related to [Fig 6](#pbio.3000563.g006){ref-type="fig"}).

\(A\) The published database (GSE14323) \[[@pbio.3000563.ref048]\] was utilized to evaluate the mRNA expression of predicted upstream regulators (normal, *n* = 19; cirrhosis, *n* = 58; HCC, *n* = 38). (B-C) qRT-PCR analysis of *RORα* (B) and *Ccl2* (C) expression in AML12 cells after RORα overexpression. The mRNA expression was normalized to *Gapdh* (*n* = 4 per group). (D) qRT-PCR analysis of *Ccl2* expression in shCtrl and shMed23 AML12 cells after *RORα* knockdown. The expression was normalized to *Gapdh* (*n* = 3 per group). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. For underlying data, see [S1 Data](#pbio.3000563.s005){ref-type="supplementary-material"} file. AML12, alpha mouse liver 12; Ccl, C-C motif chemokine ligand; *Gapdh*, glyceraldehyde 3-phosphate dehydrogenase; HCC, hepatocellular carcinoma; MED23, Mediator complex subunit 23; qRT-PCR, quantitative real-time PCR; RORα, RAR-related orphan receptor alpha; shCtrl, negative control vector containing scrambled shRNA; shMed23, shRNA against Med23.

(TIF)

###### 

Click here for additional data file.

###### Numerical data used in all the figures.

(XLSX)

###### 

Click here for additional data file.

###### List of genes with log~2~FC ≥1 or ≤1 and *P* \< 0.05 found by RNA-seq in *med23*^Δli^ mice livers compared with controls following 24 hours of CCl~4~ treatment.

CCl~4~, carbon tetrachloride; FC, fold change; *med23*, Mediator complex subunit 23; *med23*^Δli^, liver-specific knockout of *Med23*; RNA-seq, RNA sequencing.

(XLS)

###### 

Click here for additional data file.

###### The upstream regulator analysis by IPA on significantly up-regulated genes with a 2-fold increase in expression after hepatic *Med23* deletion.

IPA, Ingenuity Pathway Analysis; *Med23*, Mediator complex subunit 23.

(XLS)

###### 

Click here for additional data file.

###### List of shRNA targeting sequences.

shRNA, short hairpin RNA.

(DOCX)

###### 

Click here for additional data file.

###### List of siRNA targeting sequences.

siRNA, small interfering RNA.

(DOCX)

###### 

Click here for additional data file.

###### List of primers used in the ChIP-qPCR analysis.

ChIP-qPCR, chromatin immunoprecipitation followed by quantitative PCR.

(DOCX)

###### 

Click here for additional data file.

###### List of primers used in the qRT-PCR analysis.

qRT-PCR, quantitative real-time PCR.

(DOCX)

###### 

Click here for additional data file.

###### Supporting methods.

(PDF)

###### 

Click here for additional data file.

###### The raw images of western blotting displayed in this study.

(PDF)

###### 

Click here for additional data file.

We thank Drs. Li-Jian Hui, Hong-bin Ji, Gao-xiang Ge, and Li-ming Sun (Shanghai Institute of Biochemistry and Cell Biology, China) for helpful discussions and their gifts of primary antibodies and Dr. Jiu-cun Wang (Fudan University, China) for helpful advice and discussion. We also thank Dr. Sung Hee Baek (Seoul National University, Korea) for the generous gifts of plasmids.

AML12
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α-SMA

:   alpha-smooth muscle actin

AST

:   aspartate aminotransferase

CCL

:   C-C motif chemokine ligand

CCl~4~

:   carbon tetrachloride

CCR

:   C-C motif chemokine receptor

CEBPB

:   CCAAT enhancer binding protein beta

ChIP

:   chromatin immunoprecipitation

cIAP

:   cellular inhibitor of apoptosis protein

Col

:   collagen

Col1a1

:   collagen type I alpha 1 chain

Col3a1

:   collagen type III alpha 1 chain

CRISPR/Cas9

:   clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9

CXCL

:   C-X-C motif chemokine ligand

Cxcr2

:   C-X-C motif chemokine receptor 2

ECM

:   extracellular matrix

EHMT2

:   euchromatic histone-lysine N-methyltransferase 2

GAPDH

:   glyceraldehyde 3-phosphate dehydrogenase

GSEA

:   gene set enrichment analysis

HCC

:   hepatocellular carcinoma

HDAC

:   histone deacetylase

HE

:   hematoxylin--eosin

HFD

:   high-fat diet

Hgf

:   hepatocyte growth factor

HSC

:   hepatic stellate cell

HSP70

:   hot shock protein 70

Il-6

:   interleukin 6

IPA

:   Ingenuity Pathway Analysis

MCD

:   methionine and choline-deficient

MED23

:   Mediator complex subunit 23

*med23*^Δli^

:   liver-specific knockout of *Med23*

*med23*^f/f^

:   *med23-*floxed

MMP

:   matrix metalloproteinase

NASH

:   nonalcoholic steatohepatitis

NF-κB

:   nuclear factor kappa-light-chain-enhancer of activated B cells

NK

:   natural killer

PCNA

:   proliferating cell nuclear antigen

Pdgfβ

:   platelet-derived growth factor beta

Pdgfrβ

:   platelet-derived growth factor receptor beta

Pol II

:   RNA polymerase II

PPARα

:   peroxisome proliferator--activated receptor alpha

qRT-PCR

:   quantitative real-time PCR

RANTES

:   regulated upon activation normal T cell expressed and secreted factor

REST

:   RE1 silencing TF

γ-H2AX

:   phosphorylation of the histone variant H2AX

RNAi

:   RNA interference

RORα

:   RAR-related orphan receptor alpha

RORE

:   RORα response element

sg

:   staggerer

siRNA

:   small interfering RNA

TF

:   transcription factor

Tgfβ1

:   transforming growth factor beta 1

Tgfβr1

:   transforming growth factor beta receptor 1

TIMP

:   tissue inhibitor of metalloproteinase

Tnfα

:   tumor necrosis factor alpha
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7 Jun 2019

Dear Dr WANG,

Thank you for submitting your manuscript entitled \"The Mediator subunit MED23 regulates inflammatory responses and liver fibrosis\" for consideration as a Research Article by PLOS Biology.

Your manuscript has now been evaluated by the PLOS Biology editorial staff as well as by an academic editor with relevant expertise and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the \'Submissions Needing Revisions\' folder on your homepage. Please click \'Revise Submission\' from the Action Links and complete all additional questions in the submission questionnaire.

Please re-submit your manuscript within two working days, ie. by Jun 09 2019 11:59PM.

Login to Editorial Manager here: <https://www.editorialmanager.com/pbiology>

During resubmission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit <http://journals.plos.org/plosbiology/s/preprints> for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF when you re-submit.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review.

Feel free to email us at <plosbiology@plos.org> if you have any queries relating to your submission.

Kind regards,

Di Jiang

PLOS Biology
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17 Jul 2019

Dear Dr WANG,

Thank you very much for submitting your manuscript \"The Mediator subunit MED23 regulates inflammatory responses and liver fibrosis\" for consideration as a Research Article at PLOS Biology. Your manuscript has been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by three independent reviewers.

In light of the reviews (below), we will not be able to accept the current version of the manuscript, but we would welcome resubmission of a revised version that takes into account the reviewers\' comments. Our Academic Editor advises that you should include another injury model, primary hepatocyte data and data to show that this is relevant to human liver disease. It is not necessary to provide evidence that this is pathway is dysregulated in human disease, but you are encouraged to provide it if it is already available as it will increase the impact of the study. We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers\' comments. Your revised manuscript is also likely to be sent for further evaluation by the reviewers.

Your revisions should address the specific points made by each reviewer. Please submit a file detailing your responses to the editorial requests and a point-by-point response to all of the reviewers\' comments that indicates the changes you have made to the manuscript. In addition to a clean copy of the manuscript, please upload a \'track-changes\' version of your manuscript that specifies the edits made. This should be uploaded as a \"Related\" file type. You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

Before you revise your manuscript, please review the following PLOS policy and formatting requirements checklist PDF: <http://journals.plos.org/plosbiology/s/file?id=9411/plos-biology-formatting-checklist.pdf>. It is helpful if you format your revision according to our requirements - should your paper subsequently be accepted, this will save time at the acceptance stage.

Please note that as a condition of publication PLOS\' data policy (<http://journals.plos.org/plosbiology/s/data-availability>) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

For manuscripts submitted on or after 1st July 2019, we require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article\'s figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: <https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements>.

Upon resubmission, the editors will assess your revision and if the editors and Academic Editor feel that the revised manuscript remains appropriate for the journal, we will send the manuscript for re-review. We aim to consult the same Academic Editor and reviewers for revised manuscripts but may consult others if needed.

We expect to receive your revised manuscript within two months. Please email us (<plosbiology@plos.org>) to discuss this if you have any questions or concerns, or would like to request an extension. At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not wish to submit a revision and instead wish to pursue publication elsewhere, so that we may end consideration of the manuscript at PLOS Biology.

When you are ready to submit a revised version of your manuscript, please go to <https://www.editorialmanager.com/pbiology/> and log in as an Author. Click the link labelled \'Submissions Needing Revision\' where you will find your submission record.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Di Jiang

PLOS Biology

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer remarks:

Reviewer \#1: Wang et al, investigated the role of the MED23 subunit of the transcriptional Mediator complex in CCl4-induced liver injury. Mice with hepatic Med23 deletion exhibited aggravated CCl4-induced

liver fibrosis, enhanced inflammation and increased hepatocyte regeneration. The authors suggest that this phenotype is mediated by MED23-induced suppresses of orphan nuclear receptor RORα, which regulates the activation of liver fibrosis-related chemokines CCL5 and CXCL10.

Major points

1\. Half of the paper is focusing on the CCl4 responses in MED23-deleted mice that show increased HSC activation, fibrosis, inflammation and hepatocyte proliferation while hepatocyte apoptosis is reduced (Fig.1-4, half of the figures). While this data is relevant, most of this data is descriptive and may be related to the same mechanisms, meaning that it is likely looking at the same observation from different angles.

2\. The paper relies on a single model and the rationale for studying MED23 is not well explained. The authors should employ more liver injury models to exclude that their findings are specific to CCl4, a standardized model for liver fibrosis research but without much human relevance. Moreover, they should analyze MED23 in patients. It is not clear at all whether MED23 activity is altered in human fibrosis and contributes to disease progression.

3\. The authors do not sufficiently investigate whether MED23 may simply regulate responses to CCl4 and liver injury. The authors show ALT levels in the chronic CCl4 model, where liver injury is typically low towards the end of experiments and where differences may be difficult to reveal. There is no data on serum ALT in the acute injury models and not investigation of key factors that regulate CCl4 metabolization and liver injury such as Cyp expression/activity. Moreover, the assessment of apoptosis by TUNEL assay and cleaved caspase is not highly relevant as most of CCl4-induced cell death is necrosis. In light of these, it would also have been advantageous to use additional models that do not rely on biactivation of a toxin and/or mostly necrotic cell death (see comments above).

4\. The clodronate and in vitro experiments do not conclusively prove a role for MED23 via the regulation of hepatocyte Ccl5 and Cxcl10. The authors should have analyzed this in primary hepatocytes and possbily used single cell RNA-seq to compare Ccl5 and Cxcl10 expression between MED23 and floxed controls as well as between hepatocytes and other cell types in the MED23-deleted mice - this way they could have strengthened their hypothesis that hepatocytes represent the main Ccl5- and Cxcl10-secreting cell type in mice with MED23 in hepatocytes. Finally, it would have been important to show the role of Ccl5 and/or Cxcl10 by deleting these in hepatocytes in vivo - which can nowadays be achieved by hepatocyte-specific silencing or deletion methods without lengthy breedings.

5\. The authors found that Hgf, was higher in MED23-deleted livers than in control livers. It is not clear why this is the case as HGF is normally expressed by stellate cells and endothelial cells. As Hgf is an important modulator of liver injury and regeneration, this could also represent a major mechanism by which MED23 regulates responses to liver injury, rather than the postulated Ccl5 and Cxcl10 pathway in hepatocytes.

Minor points

1\. The authors state "the expression of Desmin, another marker of HSCs activation, was also higher in med23Δli mouse livers than in med23f/f mouse livers". Desmin is not a marker of activation - it is a marker of HSC and an increase may reflect an increased number of HSC in injured livers.

Reviewer \#2: Liver fibrosis is a wound-healing response that is a consequence of chronic liver diseases. Despite the widespread of this disease, the underlying molecular mechanisms remain largely unknown. Development of novel effective therapies for liver fibrosis requires identifying effective molecular targets. The focus of this research is the study of the molecular mechanism underlying liver fibrosis that is a relevant and important issue.

The manuscript "The Mediator subunit MED23 regulates inflammatory responses and liver fibrosis" is dedicated to studying of the role MED23 subunit of the Mediator complex in the development of experimental liver fibrosis. The authors showed that mice with hepatic Med23 deletion exhibited aggravated CCl₄-induced liver fibrosis. The manuscript provides evidence that MED23 negatively regulates the expression of the hepatic chemokines CCL5 and CXCL10 via suppressing the activity of the retinoid-related orphan nuclear receptor, RORα.

In summary, this manuscript is of value for the further development of our knowledge of the molecular mechanism underlying liver fibrosis and will help the development of more effective treatment options. I would recommend the manuscript for publication, but I have the following comments.

CRITIQUE

My main problem with this manuscript is that the authors made several deficiencies, which cast doubt on the conclusions and correctness of the model proposed.

1\. Necessary to give data about the number of mice in all experiments.

2\. Fig 6F. Necessary to show Western-Blot for proving the effectivity of the knocked down Rora in protein level.

3\. Fig 6I. Necessary to describe this experiment with all details in Materials and Methods. I have doubts about the conclusions made by the authors. Controls have significant differences. It should be discussed in the manuscript with an explanation. In the current moment, conclusion about a functional interaction between RORα and MED23 in controlling Ccl5 and Cxcl10 expression needs additional experiments.

4\. Fig 6J. The dual luciferase reporter assay should be described in Materials and Methods.

5\. Fig 6K. This experiment should be described with details in the manuscript.

6\. Fig 7A. Necessary to show a base level of signal for ChIP on non-promoter site of the genome.

7\. I would like to ask the authors to provide more discussion in the text. I highly recommend expanding the Introduction part and give more information about the factors used in the work.

8\. In this manuscript, a significant part of the data is the results of the qRT-PCR. I would like to ask the authors to pay more intention for presenting this type of data. Nowadays good practice to use two or three genes for normalization especially if the differences between experiment and control less than 2-folds.

Reviewer \#3: The authors study the role of Med23 in experimental models of liver fibrosis (carbon tetrachloride) in conditional knock out mice using Albumin-CRE, Med23 flox/flox mice. The authors find that deletion of Med23 in hepatocytes and cholangiocytes leads to increased liver fibrosis, decreased apoptosis but increased hepatocyte proliferative activity and increased inflammatory activity, though the characterization of inflammatory cell composition remains a bit superficial. In well designed in vitro studies using murine hepatocyte cell line AML12 and other models, the authors show that Med23 cooperates with ROR� in negatively regulating cytokines CCL5 and CXCL10. The authors show that Med23 deletion causes decreased H3K9me2 occupancy among the promoter of CCL5 and CXLC10 thus identifying novel mechanism for Med23.

Though the authors ultimately do not show the biological relevance of Med23-CCL5/CXLC10 axis in liver fibrosis and inflammation e.g. by showing abrogation of increased liver fibrosis in double knock out mice of both Med23 and CCL5/CXCL10 or data on Med23 expression levels in human liver datasets from public databases (Suppl. Fig. 3), the shown data are of very good quality and experiments are well designed. The conclusions are sound and the manuscript well written with the topic within the journals scope, I thus recommend the acceptance of the manuscript for publication.

Minor comments:

additional information regarding the catalog numbers of siRNA / plasmids used to knock down targets would be informative for readers interested in replicating the studies.

10.1371/journal.pbio.3000563.r003
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20 Sep 2019

###### 

Submitted filename: rebuttal letter.docx

###### 

Click here for additional data file.
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29 Oct 2019

Dear Dr WANG,

Thank you for submitting your revised Research Article entitled \"Mediator MED23 regulates inflammatory responses and liver fibrosis\" for publication in PLOS Biology. I have now obtained advice from two of the original reviewers and have discussed their comments with the Academic Editor.

The reviews are included below. We recognise the concerns that continue to be raised by reviewer 1, but after discussing them with the academic editor, we think that these can be satisfactorily addressed by ensuring that these potential limitations are clearly flagged for the reader. We will probably accept this manuscript for publication, assuming that you will modify the manuscript to address the remaining points raised by reviewer 1. Please also make sure to address the data and other policy-related requests noted at the end of this email.

We expect to receive your revised manuscript within two weeks. Your revisions should address the specific points made by reviewer 1. In addition to the remaining revisions and before we will be able to formally accept your manuscript and consider it \"in press\", we also need to ensure that your article conforms to our guidelines. A member of our team will be in touch shortly with a set of requests. As we can\'t proceed until these requirements are met, your swift response will help prevent delays to publication.

Upon acceptance of your article, your final files will be copyedited and typeset into the final PDF. While you will have an opportunity to review these files as proofs, PLOS will only permit corrections to spelling or significant scientific errors. Therefore, please take this final revision time to assess and make any remaining major changes to your manuscript.

NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines:

<https://journals.plos.org/plosbiology/s/supporting-information>

Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

<https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/>

Please note that an uncorrected proof of your manuscript will be published online ahead of the final version, unless you opted out when submitting your manuscript. If, for any reason, you do not want an earlier version of your manuscript published online, uncheck the box. Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.

To submit your revision, please go to <https://www.editorialmanager.com/pbiology/> and log in as an Author. Click the link labelled \'Submissions Needing Revision\' to find your submission record. Your revised submission must include a cover letter, a Response to Reviewers file that provides a detailed response to the reviewers\' comments (if applicable), and a track-changes file indicating any changes that you have made to the manuscript.

Please do not hesitate to contact me should you have any questions.

Sincerely,

Di Jiang

PLOS Biology

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

ETHICS STATEMENT:

Please add an Ethics Statement subsection at the beginning of the Methods section. The Ethics Statements in the submission form and Methods section of your manuscript should match verbatim.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

DATA POLICY:

Please also ensure that figure legends in your manuscript include information on where the underlying data can be found, and ensure your supplemental data file/s has a legend.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer remarks:

Reviewer \#1: While the authors did additional work including a second model, most of my concerns remain.

1\. The second model (MCD model) was not included in the actual paper and mechanisms seem to be different from the CCl4 model and not be mediated by the proposed inflammatory mechanism. Moreover, the MCD model is nowadays viewed as inadequate model of NASH fibrosis and other dietary models are preferred (but it is adequate for purely mechanistic studies on fibrosis)

2\. The authors have not convinced this reviewer that the main role of MED23 is not related to protection from injury. This appears to be THE driver of the phenotype - everything else is likely secondary unless proven otherwise by functional experiments (see also point below).

3\. This reviewer is not convinced that hepatocyte-secreted CCl5 and CXCL10 are the main drivers of fibrogenesis in this model. First of all, hepatocytes are not thought to be the main source of these chemokines in the liver. Second of all, hepatocyte isolations from CCl4-treated livers are inherently contaminated with inflammatory cells. The suggestion of using single cell RNA-seq as a platform that can avoid these problems was not taken up by the authors. In the absence of single cell RNA-seq analysis, the authors would need to provide evicence for this unlikely hypothesis, e.g. by hepatocyte-specific silencing of CCl5 and CXCL10 (which can nowadays be achieved without crossing mice, e.g. by AAV8- or GalNAc-mediated silencing).

Reviewer \#2: The manuscript "Mediator MED23 regulates inflammatory responses and liver fibrosis" was modified, taking into account all the comments. The authors have conducted additional experiments to cement their findings further, as suggested by editors and reviewers. The text of the manuscript was corrected and significantly improved. I recommend this manuscript to be accepted for publication in its current form.

10.1371/journal.pbio.3000563.r005
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###### 

Click here for additional data file.
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15 Nov 2019

Dear Dr WANG,

On behalf of my colleagues and the Academic Editor, Luke A Noon, I am pleased to inform you that we will be delighted to publish your Research Article in PLOS Biology.

The files will now enter our production system. You will receive a copyedited version of the manuscript, along with your figures for a final review. You will be given two business days to review and approve the copyedit. Then, within a week, you will receive a PDF proof of your typeset article. You will have two days to review the PDF and make any final corrections. If there is a chance that you\'ll be unavailable during the copy editing/proof review period, please provide us with contact details of one of the other authors whom you nominate to handle these stages on your behalf. This will ensure that any requested corrections reach the production department in time for publication.

Early Version

The version of your manuscript submitted at the copyedit stage will be posted online ahead of the final proof version, unless you have already opted out of the process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with <biologypress@plos.org>. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit <http://www.plos.org/about/media-inquiries/embargo-policy/>.

Thank you again for submitting your manuscript to PLOS Biology and for your support of Open Access publishing. Please do not hesitate to contact me if I can provide any assistance during the production process.

Kind regards,

Hannah Harwood

Publication Assistant,

PLOS Biology

on behalf of

Di Jiang,

Associate Editor

PLOS Biology

[^1]: The authors have declared that no competing interests exist.
